Company Overview and News

731
GME Stock Price - GameStop Corp. Cl A Stock Quote (U.S.: NYSE) - MarketWatch

2018-06-18 marketwatch
Electronic Arts Inc. for the first time will let people subscribe to play its newest PC games, embracing a model analysts believe could eventually alter how people access and select which games to play.
EA DVAX MDRX SRCI SYRG AMD FINL NFX GME PLUG

41
Clearside Biomedical: Upside Into Q4 Data And NDA Submission

2018-06-17 seekingalpha
Year to date shares of Clearside Biomedical (CLSD) have risen by 50%, having pulled back after at one point doubling due to positive phase 3 data reported in March.
DVAX CLSD

40
Dynavax Gives A Welcome Business Update

2018-06-16 seekingalpha
Ostrach provided useful updates on the Heplisav-B commercialization effort, in addition to adding some valuable color to the results of the recently concluded SD-101 melanoma study.
DVAX

191
7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.

2018-06-13 investorplace
Analysts reiterate their stock recommendations quite a bit. So when a stock is upgraded, or more rarely, downgraded, the market takes note. This is especially the case for a market-leading stock like Facebook, Inc. (NASDAQ:FB) — see below!
NI WFCNP NEWR FB WFC.PRL WFC.PRJ WFC.PRT WFC.PRR DVAX WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV ABBV WFC WFC.WS SRPT VYGR ABBV MDCA

39
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference

2018-06-11 globenewswire
BERKELEY, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Michael Ostrach, Dynavax’s Chief Financial Officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL. The presentation will be webcast live and will occur on Tuesday, June 12, 2018 at 2:10 p.m. CT.
DVAX

40
DVAX / Dynavax Technologies Corp. S-8

2018-06-08 sec.gov
S-8 As filed with the Securities and Exchange Commission on June 8, 2018 Registration No. 333 -
DVAX

633
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY

44
DVAX / Dynavax Technologies Corp. FORM 8-K (Current Report)

2018-06-05 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DVAX

39
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

2018-06-04 globenewswire
Overall Response Rate (ORR) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of SD-101
DVAX

670
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

2018-05-31 seekingalpha
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.
SGEN NKTR ATRS BLCM VRTX NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE RDUS BMY CALD MOR EXEL GILD BLUE XNCR SLDB NBIX CRSP GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY

699
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

2018-05-22 seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.
SGEN SCD NKTR ATRS NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN FCSC CELG GSK BLUE RDUS BMY EXEL BLUE XNCR SM NBIX GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY

39
The Market Completely Misunderstood The Dynavax SD-101 Data

2018-05-22 seekingalpha
On May 16, DVAX released an abstract for an upcoming presentation to be delivered at the June ASCO meeting about trial of SD-101 and Keytruda in advanced melanoma.
DVAX

39
Reader Inquiry: What's The Outlook For Core Biotech Holding Dynavax Technologies?

2018-05-21 seekingalpha
The stock has fallen by 17% over the past three years and is in the red by 8% year-to-date.
DVAX

39
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting

2018-05-16 globenewswire
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy
DVAX

DVAX : Dynavax Technologies Stock Analysis and Research Report

2017-10-16 - Asif

Dynavax Technologies is a clinical-stage immunotherapy company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Dynavax current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor effects at both the injected site and at distant sites. Dynavax is conducting a clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with a range of treatments, including checkpoint inhibitors and...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to DVAX / Dynavax Technologies Corp. on message board site Silicon Investor.

Dynavax DVAX ADXS - Advaxis, Inc. (Bulls Board)
CUSIP: 268158201